Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in P-III Study for Episodic Cluster Headache

Shots:

• The P-III study results involve assessing of Emgality (300 mg) vs PBO in 106 patients in a ratio (1:1) with an average 17.8 vs 17.3 weekly cluster headache attacks respectively
• The P-III study results: @1-3wks. reduction in weekly cluster headache attacks (8.7 vs 5.2); @3wks. reduction in the frequency of headache attack by ≥ 50% (71.4% vs 52.6%), published in the New England Journal of Medicine
• Emgality is a mAb targeting CGRP and has received EMA’s approval for the prophylaxis of migraine in Nov’2018 and FDA’s approval for migraine and episodic cluster headache in adults in Sept’2018 and Jun’2019 respectively

Click here to read full press release/ article | Ref: Eli Lilly | Image: Kramer-Design